<DOC>
	<DOCNO>NCT01903473</DOCNO>
	<brief_summary>The immune system offensive defensive capacity . In bone marrow transplantation , offensive cell donor graft may attack host 's organ , lead complication know Graft versus Host Disease ( GVDH ) . At present , patient receive steroid treatment combat tricky situation . Nevertheless , patient respond therapy . Recently , show immune system cell defensive capacity help prevent occurrence GVDH . This study aim evaluate protective cell together non-standard immunosuppressor improve clinical condition suppress activity offensive cell graft .</brief_summary>
	<brief_title>Donor Regulatory T Cells Infusion Patients With Chronic Graft-versus-host Disease ( GVHD )</brief_title>
	<detailed_description>1 . Collection isolation T regulatory cell carry Laboratory Cell Gene Therapy ( LTCG ) University Liege . The following laboratory analysis perform lymphocyte collection well start , intermediate final fraction Treg selection : - Nucleated cell count differential automate cell counter ; - FACS analysis determination % cell ( total WBC ) marker : CD20-FITC , CD14-PE , CD15-PE , CD56-PE , CD45-VioBlue , CD8-APC , PropidiumIodid , T reg Detection Kit ( CD4/CD25/CD127 ) , Treg Detection ( CD4/CD25/Foxp3 ) . - Treg phenotype use follow marker : CD127 , CD45RA , CCR4 , CCR7 KI67 . - Estimation Treg function . - Cell viability trypan blue exclusion . 2 . Treg release The following criterion meet Treg release : - ≥ 0.5 x106 cells/kg recipient ; - ≥ 55 % CD4+FoxP3 3 . Treg injection : Treg administer fresh . A dose ≥ 0.5 x106 cells/kg recipient Treg cell ideally administer . 4 . Patients Follow 4.1 . Quality control Treg product : quality control Treg cell include microscopy , nucleate cell count differential , cell viability testing , microbiology test ( include standard virology , bacterial culture detection mycoplasmal enzyme bioluminescence , endotoxin testing , karyotype FACS analysis state point 1 ) 4.2 . Toxicities cell infusion : Potential toxicity associate Treg infusion carefully monitor per institution 's standard document infusion report and/or SAE report form . No dosage modification schedule . 5 . Clinical data : - Duration hospitalization , infection , serious complication , death survival record . - Incidence , time severity acute GVHD follow Treg cell infusion ( DTI ) , treatment outcome ; - Evolution chronic GVHD , treatment outcome . More specifically , chronic GVHD ( include current immunosuppressive therapy ) assess organ accord NIH consensus : - The day inclusion ( first day rapamycin administration ) . - 3 4 week rapa onset ( DTI ) . - 1 week DTI ( DTI arm ) 4-5 week rapamycin onset ( control arm ) . - 3 week DTI ( DTI arm ) 6-7 week rapamycin onset ( control arm ) . - 3 , 6 12 month rapamycin onset . - Incidence , time severity secondary cytopenia , treatment outcome ; - Incidence , time severity bacterial , viral , fungal protozoal infection - Duration hospitalization ; - Evolution primary malignant disease : response CR time inclusion , relapse , treatment outcome ; - Any serious complication associate transplant procedure ; - Death survival .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Signed informed consent . Grafts HLAidentical sibling HLAmatched unrelated donor ( 1 10 HLAmismatch allow ) . ≥ 18 year age Steroidrefractory steroidresistant chronic GVHD define : development 1 new site disease treat chronic GVHD , progression exist site disease receive treatment chronic GVHD , failure improve despite least 1 month standard treatment chronic GVHD . No prior failure rapamycine treatment chronic GVHD No contraindication use rapamycin . GFR &gt; 25 mL/min . Karnofsky performance score ≥ 70 % . DLCO &gt; 35 % need supplemental continuous oxygen . No active posttransplant microangiopathy previous microangiopathy rapamycine . HIV seropositivity . Fungal infection radiological progression treatment amphotericine B active azoles &gt; 1 month . Other uncontrolled infection . Progression hematological malignancy . Uncontrolled hypertriglyceridemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Allogeneic hematopoietic cell transplantation</keyword>
	<keyword>GVHD</keyword>
	<keyword>Regulatory T cell</keyword>
	<keyword>Steroid refractory</keyword>
	<keyword>Rapamycin</keyword>
	<keyword>Immune recovery</keyword>
	<keyword>Infusion</keyword>
	<keyword>HLA-identical sibling</keyword>
	<keyword>HLA-matched unrelated donor</keyword>
</DOC>